1GDA logo

Zevra Therapeutics DB:1GDA Stock Report

Last Price

€5.35

Market Cap

€220.7m

7D

-2.7%

1Y

6.7%

Updated

25 Mar, 2024

Data

Company Financials +

Zevra Therapeutics, Inc.

DB:1GDA Stock Report

Market Cap: €220.7m

1GDA Stock Overview

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

1GDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Zevra Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zevra Therapeutics
Historical stock prices
Current Share PriceUS$5.35
52 Week HighUS$6.45
52 Week LowUS$3.82
Beta1.82
1 Month Change-13.71%
3 Month Change22.15%
1 Year Change6.66%
3 Year Change-31.41%
5 Year Change-77.56%
Change since IPO-98.09%

Recent News & Updates

Recent updates

Shareholder Returns

1GDADE PharmaceuticalsDE Market
7D-2.7%3.0%1.3%
1Y6.7%-25.6%6.4%

Return vs Industry: 1GDA exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.

Return vs Market: 1GDA matched the German Market which returned 6.4% over the past year.

Price Volatility

Is 1GDA's price volatile compared to industry and market?
1GDA volatility
1GDA Average Weekly Movement9.1%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1GDA has not had significant price volatility in the past 3 months.

Volatility Over Time: 1GDA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200634Neil McFarlanehttps://zevra.com

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

Zevra Therapeutics, Inc. Fundamentals Summary

How do Zevra Therapeutics's earnings and revenue compare to its market cap?
1GDA fundamental statistics
Market cap€220.68m
Earnings (TTM)-€36.86m
Revenue (TTM)€15.30m

14.4x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GDA income statement (TTM)
RevenueUS$16.56m
Cost of RevenueUS$1.09m
Gross ProfitUS$15.47m
Other ExpensesUS$55.39m
Earnings-US$39.92m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-0.96
Gross Margin93.43%
Net Profit Margin-241.00%
Debt/Equity Ratio65.0%

How did 1GDA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.